Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

  • 130 Accesses

Correction to: Journal of Neurology https://doi.org/10.1007/s00415-019-09602-8

The original version of this article unfortunately contained a mistake in Table 1.

Table 1 Disease characteristics of autonomic endpoints at baseline

Units for albumin were given as g/dL. It should be g/L.

Author information

Correspondence to Alejandra González-Duarte.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

González-Duarte, A., Berk, J.L., Quan, D. et al. Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. J Neurol 267, 713–714 (2020). https://doi.org/10.1007/s00415-020-09715-5

Download citation